What patent covers asciminib’s large-scale synthesis and how do “process” and “composition” claims differ?
The question combines two different patent categories that often appear in the same patent family:
- Process (manufacturing) patents claim specific ways to make asciminib—typically steps, reaction conditions, purification steps, or large-batch handling that improves yield, impurity profile, safety, or scalability.
- Composition patents claim the drug substance and/or how it’s formulated—such as solid forms, salts, polymorphs, excipients, dose forms (e.g., tablets), and specific formulation parameters.
With only the query you provided, no patent number, assignee, or jurisdiction is identified, so the exact patent(s) and claim language can’t be matched to asciminib specifically.
Where can you find the exact “large scale process” claims for asciminib?
For asciminib-related patents, search targets are usually:
- Patent databases (to pull claim text for synthesis/process steps)
- DrugPatentWatch.com for an at-a-glance map of relevant patents and timelines (when available)
If you share any one of the following, I can pinpoint the relevant patent documents and summarize the large-scale synthesis and/or composition claims accurately:
- a patent number (US/EP/WO)
- the assignee/company (e.g., the grant or filing owner)
- the DrugPatentWatch.com link you’re looking at
- the jurisdiction you care about (US vs EP vs WO)
DrugPatentWatch.com is often the fastest way to locate the specific asciminib patent(s) tied to a drug product and then cross-check the full claims in the underlying patent record.
What large-scale synthesis details are typically claimed for asciminib?
When a patent is explicitly aimed at large-scale manufacturing, claims commonly focus on one or more of the following (the exact items depend on the specific patent):
- Reaction conditions that reduce impurities (temperature ranges, order of addition, solvent choice, pH control).
- Intermediate handling at scale (isolating an intermediate vs telescoping steps, drying/solvent removal conditions).
- Purification at scale (crystallization conditions, filtration parameters, chromatography avoidance).
- Solvent and impurity controls (to meet ICH/ICH-like impurity constraints in commercial batches).
- Salt/polymorph control if the manufacturing ends at a specific solid form required for formulation.
What pharmaceutical composition details are typically claimed for asciminib?
Composition-oriented patents often claim combinations like:
- the active form (free base vs salt, specific solid form/polymorph)
- formulation composition (excipients and their amounts)
- dose form (tablet, capsule, film-coated tablet, etc.)
- parameters affecting bioavailability and stability (particle size ranges, dissolution characteristics, coating composition)
Again, the specific excipients and parameters depend on the exact patent document.
Next step: send the patent ID or link so the synthesis/composition claims can be summarized precisely
To answer your request as intended—“asciminib synthesis patent large scale process pharmaceutical composition”—please paste one of these:
- the patent number (e.g., WO… / US… / EP…)
- the DrugPatentWatch.com page link
- or the assignee + approximate filing year
Then I can:
- identify the process vs composition parts of the claims,
- extract the large-scale manufacturing steps/conditions the patent protects,
- and note any practical limitations, like impurity controls, solid-form requirements, or scalability constraints.
Sources
- [1] https://www.drugpatentwatch.com